Inorganic Chemistry
Article
diisopropylethylamine (1.9 mL, 7.4 mmol). The resulting mixture was
refluxed under an inert atmosphere for 12 h and evaporated to dryness.
The residual solid was dissolved in dichloromethane (180 mL) and
washed successively with half-sat. NH4Cl (180 mL), water (50 mL), and
brine (50 mL). The organic phase was dried over Na2SO4, filtered, and
evaporated to dryness. The crude solid was purified by column
chromatography (silicagel, CH2Cl2:CH3OH = 100:0→98:2) to give 11
as a pale yellow solid (2.6 g, 3.1 mmol, 79%). ESI-MS (CHCl3/MeOH):
m/z 862.3 ([M+H]+).
(CDCl3) δ/ppm: 12.8, 14.3, 15.4, 15.5, 39.6, 39.8, 39.9, 40.6, 42.2, 42.8,
65.6, 110.1, 110.2, 110.3, 118.8, 120.0, 120.1, 122.4, 123.3, 124.9, 125.0,
125.1, 125.5, 125.6, 134.5, 134.8, 135.5, 136.2, 136.6, 137.9, 142.9, 143.0,
143.1, 149.3, 149.4, 149.8, 149.9, 150.2, 154.4, 168.5. ESI-MS (CH2Cl2/
MeOH 9:1): m/z 732.3 ([M+H]+).
Preparation of 6-(5-{2-[6-(5-Chloromethyl-1-ethyl-1H-ben-
zoimidazol-2-yl)-pyridin-2-yl]-1-ethyl-1H-benzoimidazol-5-yl-
methyl}-1-ethyl-1H-benzoimidazol-2-yl)-pyridine-2-carboxylic
Acid Diethylamide (14). A mixture of 6-(1-ethyl-5-{1-ethyl-2-[6-(1-
ethyl-5-hydroxymethyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-1H-ben-
zoimidazol-5-ylmethyl}-1H-benzoimidazol-2-yl)-pyridine-2-carboxylic
acid diethylamide (14, 2.0 g, 2.7 mmol), CH2Cl2 (80 mL) and thionyl
chloride (3.0 mL, 42 mmol) was stirred for 16 h at room temperature,
then poured into aqueous sat. NaHCO3 (650 mL). The aqueous layer
was extracted with dichloromethane (3 × 100 mL), and the combined
organic phases were washed with deionized water until neutral, dried
over Na2SO4, filtered, and evaporated to dryness. The resulting crude
compound was purified by column chromatography (silicagel, CH2Cl2/
MeOH 98:2 → 95:5) to afford 14 as a beige solid (1.95 g, 2.6 mmol,
yield 99%). 1H NMR (CDCl3) δ/ppm: 8.39 (d, 3J = 7.9 Hz, 1H), 8.30−
8.35 (m, 2H), 8.04 (t, 3J = 7.8 Hz, 1H), 7.93 (t, 3J = 7.8 Hz, 1H), 7.86 (d,
4J = 1.0 Hz, 1H), 7.74 (d, 4J = 1.0 Hz, 1H), 7.71 (s, 1H), 7.54 (dd, 3J = 7.8
Preparation of N,N-Diethyl-6-(1-ethyl-5-((1-ethyl-2-(6-(1-
ethyl-5-(methoxymethyl)-1H-benzo[d]imidazol-2-yl)pyridin-2-
yl)-1H-benzo[d]imidazol-5-yl)methyl)-1H-benzo[d]imidazol-2-
yl)picolinamide (12). N-(4-(4-(6-(diethylcarbamoyl)-N-ethylpicoli-
namido)-3-nitrobenzyl)-2-nitrophenyl)-N,N-diethyl-N-(4-(methoxy-
methyl)-2-nitrophenyl)pyridine-2,6-dicarboxamide (9, 1.77 g, 1.99
mmol) and activated metallic iron powder (2.77 g, 49.7 mmol) was
refluxed in ethanol/water/conc. hydrochloric acid (200 mL/60 mL/12
mL) for 16 h. Excess of metallic iron was filtered off and ethanol was
distilled under vacuum. Dichloromethane (150 mL) and Na2H2EDTA
(19 g, 49.7 mmol in 250 mL water) was added to the remaining solution.
The pH was adjusted to 7.0 with conc. aqueous ammonia. Conc.
hydrogen peroxide (30% in water, 5 mL) was added dropwise under
vigorous strirring, and the pH raised to 8.5 with conc. aqueous ammonia.
The organic layer was separated, and the aqueous phase was extracted
with dichloromethane (3 × 200 mL). The combined organic phases
were washed with water (200 mL), dried over Na2SO4, filtered, and
evaporated to dryness. The crude solid was purified by column
chromatography (silicagel, CH2Cl2:CH3OH = 100:0→97:3) to give 12
as a beige solid (1.2 g, 1.6 mmol, yield 81%). 1H NMR (CDCl3) δ/ppm:
8.37 (dd, 3J = 8.0 Hz, 4J = 1.0 Hz, 1H), 8.33 (dd, 3J = 7.8 Hz, 4J = 1.0 Hz,
1H), 8.32 (dd, 3J = 7.9 Hz, 4J = 1.1 Hz, 1H), 8.03 (t, 3J = 7.9 Hz, 1H),
7.93 (t, 3J = 7.8 Hz, 1H), 7.81 (d, 4J = 1.0 Hz, 1H), 7.74 (d, 4J = 1.0 Hz,
1H), 7.70 (d, 4J = 1.0 Hz, 1H), 7.54 (dd, 3J = 7.7 Hz, 4J = 1.1 Hz), 7.46 (d,
3J = 8.3 Hz, 1H), 7.35−7.39 (m, 3H), 7.24−7.27 (m, 2H), 4.72−4.82
Hz, 4J = 1.0 Hz, 1H), 7.43 (dd, 3J = 8.3 Hz, 4J = 0.5 Hz, 1H), 7.42 (dd, 3J
= 8.3 Hz, 4J = 1.5 Hz, 1H), 7.38 (d, 3J = 8.3 Hz, 1H), 7.37 (d, 3J = 8.3 Hz,
1H), 7.27 (t, 4J = 1.0 Hz, 1H), 7.25 (t, 4J = 1.0 Hz, 1H), 4.79 (s, 2H),
4.71−4.78 (m, 6H), 4.30 (s, 2H), 3.61 (q, 3J = 7.1 Hz, 2H), 3.35 (q, 3J =
7.1 Hz, 2H), 1.45 (t, 3J = 7.1 Hz, 3H), 1.32−1.38 (m, 6H), 1.29 (t, 3J =
7.1 Hz, 3H), 1.07 (t, 3J = 7.1 Hz, 3H). 13C NMR (CDCl3) δ/ppm: 12.8,
14.3, 15.3, 15.4, 39.5, 39.8, 39.9, 40.6, 42.2, 42.8, 47.2, 110.1, 110.2,
110.7, 120.0, 120.2, 120.6, 122.5, 124.5, 125.0, 125.7, 125.8, 132.3, 134.5,
134.8, 136.0, 136.7, 138.0, 138.2, 142.9, 143.1, 149.3, 149.7, 149.8, 150.1,
150.8, 154.5, 168.5; ESI-MS (CH2Cl2/MeOH 9:1): m/z 750.3 ([M
+H]+).
Preparation of Thioacetic acid S-[2-(6-{5-[2-(6-diethylcarba-
moyl-pyridin-2-yl)-1-ethyl-1H-benzoimidazol-5-ylmethyl]-1-
ethyl-1H-benzoimidazol-2-yl}-pyridin-2-yl)-1-ethyl-1H-benzoi-
midazol-5-ylmethyl] Ester (15). 6-(5-{2-[6-(5-Chloromethyl-1-
ethyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-1-ethyl-1H-benzoimidazol-
5-ylmethyl}-1-ethyl-1H-benzoimidazol-2-yl)-pyridine-2-carboxylic acid
diethylamide (14, 2.0 g, 2.6 mmol) was dissolved in a suspension of
potassium thioacetate (1.5 g, 13.3 mmol) in acetone (40 mL) and
dichloromethane (40 mL). The mixture was refluxed for 16 h, and then
evaporated to dryness. The resulting solid was partitioned between
dichloromethane (400 mL) and water (300 mL). The aqueous phase
was separated and extracted with dichloromethane (3 × 100 mL). The
combined organic phases were washed with brine, dried over Na2SO4,
filtered, evaporated, and the residue was purified by column
chromatography (silicagel, CH2Cl2/MeOH 100:0 → 95:5) to afford
15 as a white solid (2.0 g, 2.5 mmol, yield 96%). 1H NMR (CDCl3) δ/
ppm: 8.37 (dd, 3J = 8.0 Hz, 4J = 1.0 Hz, 1H), 8.32 (dd, 3J = 7.8 Hz, 4J =
1.0 Hz, 1H), 8.30 (dd, 3J = 7.8 Hz, 4J = 1.0 Hz, 1H), 8.02 (t, 3J = 7.8 Hz,
1H), 7.92 (t, 3J = 7.8 Hz, 1H), 7.77 (d, 4J = 1.0 Hz, 1H), 7.73 (d, 4J = 1.0
Hz, 1H), 7.70 (d, 4J = 1.0 Hz, 1H), 7.53 (dd, 3J = 7.7 Hz, 4J = 1.0 Hz,
1H), 7.35−7.40 (m, 3H), 7.30 (dd, 3J = 8.4 Hz, 4J = 1.5 Hz, 1H), 7.26
(m, 1H), 7.24 (t, 4J = 1.5 Hz, 1H), 4.71−4.78 (m, 6H), 4.30 (s, 4H), 3.60
(q, 3J = 7.1 Hz, 3H), 3.35 (q, 3J = 7.1 Hz, 2H), 2.35 (s, 3H), 1.45 (t, 3J =
7.1 Hz, 3H), 1.30−1.35 (m, 6H), 1.28 (t, 3J = 7.1 Hz, 3H), 1.07 (t, 3J =
7.1 Hz, 3H). 13C NMR (CDCl3) δ/ppm: 12.8, 14.3, 15.3, 15.4, 15.5,
30.4, 34.0, 39.6, 39.8, 39.9, 40.6, 42.2, 42.8, 110.0, 110.2, 110.4, 120.0,
120.2, 120.4, 122.4, 124.6, 124.9, 125.0, 125.1, 125.6, 125.7, 132.3, 134.5,
134.8, 135.3, 136.5, 136.6, 137.9, 138.0, 143.0, 143.1, 143.2, 149.3, 149.4,
149.8, 149.9, 150.1, 150.5, 154.4, 168.5, 195.2. ESI-MS (CH2Cl2/
MeOH 9:1): m/z 790.3 ([M+H]+).
(m, 6H), 4.62 (s, 2H), 4.30 (s, 2H), 3.61 (q, 3J = 7.1 Hz, 2H), 3.41 (s,
3H), 3.35 (q, 3J = 7.1 Hz, 2H), 1.45 (t, 3J = 7.1 Hz, 3H), 1.35 (q, 3J = 7.1
Hz, 6H), 1.28 (t, 3J = 7.1 Hz, 3H), 1.07 (t, 3J = 7.1 Hz, 3H). 13C NMR
(CDCl3) δ/ppm: 12.8, 14.3, 15.3, 15.4, 39.5, 39.8, 39.9, 40.6, 42.2, 42.8,
57.8, 75.1, 110.0, 110.1, 110.2, 119.8, 120.0, 120.2, 122.4, 123.8, 124.9,
125.0, 125.5, 125.6, 132.9, 134.5, 134.8, 135.6, 136.5, 136.6, 137.9, 138.1,
142.9, 143.1, 143.3., 149.4, 149.5, 149.9, 150.1, 150.3, 154.5, 168.5. ESI-
MS (CH2Cl2/MeOH 9:1): m/z 746.5 ([M+H]+).
Preparation of 6-(1-Ethyl-5-{1-ethyl-2-[6-(1-ethyl-5-hydrox-
ymethyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-1H-benzoimida-
zol-5-ylmethyl}-1H-benzoimidazol-2-yl)-pyridine-2-carboxylic
Acid Diethylamide (13). A mixture of N,N-diethyl-6-(1-ethyl-5-((1-
ethyl-2-(6-(1-ethyl-5-(methoxymethyl)-1H-benzo[d]imidazol-2-yl)-
pyridin-2-yl)-1H-benzo[d]imidazol-5-yl)methyl)-1H-benzo[d]-
imidazol-2-yl)picolinamide (12, 1.2 g, 1.6 mmol) in acetic anhydride/
CH2Cl2 (25 mL/25 mL) and BF3·Et2O (1.0 mL, 8 mmol) was stirred for
16 h at room temperature, then poured into an ice-cooled aqueous 1 M
KOH solution (400 mL). The aqueous layer was extracted with CH2Cl2
(2 × 50 mL). The combined organic phases were washed with deionized
water until neutral, dried over Na2SO4, filtered, and evaporated to
dryness to afford the crude acetate, which was dissolved in methanol/2
M aq. KOH (100 mL/70 mL), and stirred for 12 h at room temperature.
The methanol was distilled under vacuum, the resulting solution was
poured into brine (500 mL) and extracted with CH2Cl2 (3 × 100 mL).
The combined organic phases were washed with deionized water until
neutral, dried over Na2SO4, filtered, and evaporated to dryness. The
resulting crude compound was purified by column chromatography
(silicagel, CH2Cl2/MeOH 97:3 → 95:5) to afford 13 as a white solid
(0.9 g, 1.2 mmol, yield 76%). 1H NMR (CDCl3) δ/ppm: 8.36 (dd, 3J =
8.0 Hz, 4J = 1.0 Hz, 1H), 8.23−8.27 (m, 2H), 7.95 (t, 3J = 7.9 Hz, 1H),
7.92 (t, 3J = 7.9 Hz, 1H), 7.77 (d, 4J = 1.0 Hz, 1H), 7.74 (d, 4J = 1.0 Hz,
1H), 7.69 (d, 4J = 1.0 Hz, 1H), 7.53 (dd, 3J = 7.7 Hz, 4J = 1.0 Hz, 1H),
7.40−7.44 (m, 2H), 7.37 (d, 3J = 8.4 Hz, 1H), 7.36 (d, 3J = 8.4 Hz, 1H),
7.24 (dd, 3J = 8.3 Hz, 4J = 1.4 Hz, 2H), 4.82 (s, 2H), 4.71−4.79 (m, 6H),
4.29 (s, 2H), 3.60 (q, 3J = 7.1 Hz, 2H), 3.35 (q, 3J = 7.1 Hz, 2H), 1.45 (t,
3J = 7.1 Hz, 3H), 1.26−1.37 (m, 9H), 1.07 (t, 3J = 7.1 Hz, 3H). 13C NMR
Preparation of 6-(1-Ethyl-5-{1-ethyl-2-[6-(1-ethyl-5-mercap-
tomethyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-1H-benzoimi-
dazol-5-ylmethyl}-1H-benzoimidazol-2-yl)-pyridine-2-carbox-
ylic Acid Diethylamide (16). Thioacetic acid S-[2-(6-{5-[2-(6-
diethylcarbamoyl-pyridin-2-yl)-1-ethyl-1H-benzoimidazol-5-ylmethyl]-
1-ethyl-1H-benzoimidazol-2-yl}-pyridin-2-yl)-1-ethyl-1H-benzoimida-
zol-5-ylmethyl] ester (15, 1.1 g, 1.4 mmol) was dissolved in degassed
methanol (60 mL) containing conc. hydrochloric acid (37%, 5 mL). The
J
dx.doi.org/10.1021/ic301631n | Inorg. Chem. XXXX, XXX, XXX−XXX